Impax files Parkinson's drug


Impax Pharmaceuticals (IPXL) resubmits its NDA for RYTARY (IPX066), an extended release formulation of carbidopa and levodopa for the treatment of Parkinson's disease. The resubmission includes updated information on the product's safety and stability.

The FDA sent the company a CRL in January citing the need to re-inspect its manufacturing facility subsequent to a May 2011 warning letter.

Consensus estimates for Q1 and Q2 are earnings of $0.04/share on revenues of $108.7M and earnings of $0.26/share on revenues of $145.5M, respectively.

Consensus views for 2014 and 2015 are earnings of $0.68/share on revenues of $536.5M and $0.88/share on revenues of $566.5M, respectively.

350 mutual funds have positions, up from 315 a year ago.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs